Neuronetics announced that Japan’s Central Social Insurance Medical Council has approved the recommendation by Japan’s Ministry of Health, Labour and Welfare expert review panel to provide reimbursement for NeuroStar Advanced Therapy for the treatment of Major Depressive Disorder, or MDD, in adults. The reimbursement is expected to go into effect on or about June 1. The initial reimbursement approval for NeuroStar Advanced Therapy is expected to cover patients treated at the largest inpatient and outpatient psychiatric facilities in Japan, at the rate of JPY12,000 per session.
https://thefly.com/landingPageNews.php?id=2885237
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.